Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

These activities are further supported by the in-vivo data demonstrating that both the NKG2A and CD3 arms contribute to the ...

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes and new clinical strategies for oncologists.

From the practical wisdom of emphasising exercise to improve survival in colon cancer to the association of glucagon-like ...

The U.S. FDA has granted orphan drug designation for Eli Lilly's olomorasib for treatment of KRAS G12C-mutant non-small cell ...

First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses Elez E ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology ...

Meanwhile, the LiGeR-HN2 trial, comparing petosemtamab to investigators' choice of methotrexate, docetaxel, or cetuximab as a second- or third-line therapy for relapsed/refractory HNSCC patients ...

The firm will evaluate VS-7375 as both monotherapy and in combination with Eli Lilly's EGFR inhibitor Erbitux in the study.